VINC vs. PMCB, CHRO, TLPH, KPRX, KLTO, JAGX, BCLI, PHXM, CSCI, and AIMD
Should you be buying Vincerx Pharma stock or one of its competitors? The main competitors of Vincerx Pharma include PharmaCyte Biotech (PMCB), Chromocell Therapeutics (CHRO), Talphera (TLPH), Kiora Pharmaceuticals (KPRX), Klotho Neurosciences (KLTO), Jaguar Health (JAGX), Brainstorm Cell Therapeutics (BCLI), PHAXIAM Therapeutics (PHXM), COSCIENS Biopharma (CSCI), and Ainos (AIMD). These companies are all part of the "pharmaceutical products" industry.
Vincerx Pharma vs.
PharmaCyte Biotech (NASDAQ:PMCB) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, community ranking, valuation, risk and institutional ownership.
Vincerx Pharma has a consensus price target of $40.00, suggesting a potential upside of 3,125.81%. Given Vincerx Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Vincerx Pharma is more favorable than PharmaCyte Biotech.
Vincerx Pharma received 21 more outperform votes than PharmaCyte Biotech when rated by MarketBeat users.
In the previous week, PharmaCyte Biotech's average media sentiment score of 0.00 equaled Vincerx Pharma'saverage media sentiment score.
PharmaCyte Biotech has a beta of -0.18, suggesting that its share price is 118% less volatile than the S&P 500. Comparatively, Vincerx Pharma has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500.
Vincerx Pharma is trading at a lower price-to-earnings ratio than PharmaCyte Biotech, indicating that it is currently the more affordable of the two stocks.
PharmaCyte Biotech's return on equity of 0.76% beat Vincerx Pharma's return on equity.
34.2% of PharmaCyte Biotech shares are held by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are held by institutional investors. 1.0% of PharmaCyte Biotech shares are held by company insiders. Comparatively, 15.6% of Vincerx Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Vincerx Pharma beats PharmaCyte Biotech on 7 of the 12 factors compared between the two stocks.
Get Vincerx Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vincerx Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:VINC) was last updated on 2/22/2025 by MarketBeat.com Staff
